Under this new agreement, P&G retains a non-exclusive license
to Palomar's patent portfolio as well as a non-exclusive license
to the technology developed by Palomar before and during the five-year term of the prior agreement.
[R.sub.L], [R.sub.LN] = the revenue the licensee earns from a production that uses the technology, distinguished as [R.sub.L] for exclusive licensing and [R.sub.LN] for a non-exclusive license
The simplest is a non-exclusive license
. Simply put, a non-exclusive license
is a right to use the invention and not be sued.
Under the terms of the agreement, Galen granted Barr a non-exclusive license
to launch a generic version of Estrostep in October 2007 and Femhrt in November 2009 - each six months prior to the expiry of the patent.
With the non-exclusive license
, the Fredericksburg, Va.-based STR can now manufacture and sell a basic version of the patented Shipboard Automatic Chemical Agent Detector and Alarm (Ship ACADA) to non-federal government and commercial entities.
Karstadt also will be exclusive merchandise seller at the World Cup venues, and has gained a non-exclusive license
for textile and some fan merchandise.
Valentis (Burlingame, CA; 650-697-1900) announced that it has granted a non-exclusive license
to Medigene, AG (Martinsried, Germany; 49-89-85 65 29-00) for the company's GeneSwitch gene regulation technology.
Andrulis Research Corporation, a firm that wanted a non-exclusive license
for cisplatin, said that the government could have its cake and eat it too by giving out non-exclusive licenses
, which would lead to competition and price reductions for cisplatin, while requiring all license holders to contribute equally to a research fund that would be administered by the government.
Under the terms of the agreement, Salix will grant Teva a non-exclusive license
According to the terms of the agreements, AbbVie will grant Momenta a non-exclusive license
on specified dates to AbbVie's intellectual property relating to HUMIRA in the United States and in various other countries around the world in which AbbVie has intellectual property.
The first is an exclusive license for the commercialisation of US Patent #6,630,507 "Cannabinoids as Antioxidants and Neuroprotectants" (the "'507 Patent") to research and develop novel cannabinoid-based therapeutics to treat hepatic encephalopathy (HE); and the second is a non-exclusive license
under the same '507 Patent to treat chronic traumatic encephalopathy (CTE).